Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 15/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 15/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.57 |
| ▸ | CDC42 | P60953 | 1/20 | 0.57 |
| ▸ | RAC1 | P63000 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13038659 | 1.00 | AKR1B1 (0.59) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL9254412 | 0.88 | AKR1C3 (0.57) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL11737441 | 0.88 | AKR1C3 (0.57) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL11738055 | 0.85 | AKR1B1 (0.56) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL11470668 | 0.84 | AKR1B1 (0.57) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL27513099 | 0.84 | AKR1C3 (0.50) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL11818544 | 0.83 | KDM4E (0.54) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL11743878 | 0.81 | AKR1C3 (0.68) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL487736 | 0.81 | HDAC4 (0.54) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11741134 | 0.80 | AKR1B1 (0.64) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-7968575-B2 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2011-06-28 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7579477-B2 | Thiazole-based nitric oxide donors having alkyl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2009-08-25 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-7498445-B2 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2009-03-03 | — | — | US | disclosed |
| WO-2005055926-A2 | AMELIORATION OF CATARACTS, MACULAR DEGENERATION AND OTHER OPHTHALMIC DISEASES | OTHERA PHARMACEUTICALS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | COLBY PHARMACEUTICAL COMPANY | 2005-06-16 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| EP-0035305-A2 | Process for preparing esters of 2-(6'-methoxy-2'-naphtyl)-propionic acid via rearrangement of new ketals of 2-halo-1-(6'-methoxy-2'-naphtyl)-propan-1-one | BLASCHIM S.p.A. (IT) | 1981-09-09 | — | — | EP | disclosed |
| EP-0034270-A1 | Combinations of agents which give enhanced anti-inflammatory activity | AMERICAN CYANAMID COMPANY (US) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | C3AR1, C1R, AKR1C3 | AKR1B1 46/4885AKR1C3 3/4885AKR1C2 29/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | AKR1B1 1109/4885AKR1C3 2513/4885AKR1C2 1473/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | AKR1B1 1109/4885AKR1C3 2513/4885AKR1C2 1473/4885 |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | C1R, CRYAB, C9 | AKR1B1 103/4885AKR1C3 11/4885AKR1C2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.